Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL595925 | 0.86 | TRPA1 (0.50) | TRPA1KMT2ATSHRHSD17B10CTSK | |
| SCHEMBL29838159 | 0.84 | TRPA1 (0.43) | TRPA1KMT2ATSHRHSD17B10CTSK | |
| SCHEMBL21405137 | 0.84 | TRPA1 (0.43) | TRPA1KMT2ATSHRHSD17B10CTSK | |
| SCHEMBL1337974 | 0.84 | FOLH1 (0.45) | TRPA1KMT2ATSHRHSD17B10CTSK | |
| SCHEMBL16088896 | 0.84 | TRPA1 (0.43) | TRPA1KMT2ATSHRHSD17B10CTSK | |
| SCHEMBL21405109 | 0.82 | TRPA1 (0.42) | TRPA1KMT2ATSHRHSD17B10CTSK | |
| SCHEMBL30277283 | 0.82 | CYP2C9 (0.48) | TRPA1KMT2ACTSKMAPK1P2RX3 | |
| SCHEMBL21405105 | 0.82 | TRPA1 (0.42) | TRPA1KMT2ATSHRHSD17B10CTSK | |
| SCHEMBL19962270 | 0.82 | CYP2C9 (0.48) | TRPA1KMT2ACTSKMAPK1P2RX3 | |
| SCHEMBL23205455 | 0.80 | GPR139 (0.48) | KMT2ATSHRHSD17B10CTSKABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114872-B2 | Triazolyl aminopyrimidine compounds | ELI LILLY AND COMPANY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | DPYD, TP53, TYMP | TRPA1 3529/4885KMT2A 1133/4885TSHR 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.